Pharmacyte Biotech, INC

PharmaCyte Biotech stockholders approved an increase in equity incentive shares and authorized a potential reverse stock split at the 2026 annual meeting.

PharmaCyte Biotech, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, initiating a 180-day compliance period.

Q/C Technologies, formerly TNF Pharmaceuticals, reported significant net losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern and facing a Nasdaq minimum bid price deficiency.

PharmaCyte Biotech, Inc. stockholders approved key proposals, including an increase of 2.25 million shares for its 2022 Equity Incentive Plan and authorization for common stock issuance to comply with Nasdaq rules.

PharmaCyte Biotech invests an additional $3 million in TNF Pharmaceuticals to support its new license for a breakthrough light-speed computing platform aimed at cryptocurrency and blockchain applications.

PharmaCyte Biotech, Inc. announced a $7 million private placement of Series C convertible preferred stock and warrants, primarily from existing investors, to strengthen its balance sheet and pursue strategic alternatives.

PharmaCyte Biotech reported a significant net loss for the nine months ended January 31, 2026, while addressing an ongoing FDA clinical hold and Nasdaq minimum bid price non-compliance.

PharmaCyte Biotech, Inc. reported a significant net loss for the second quarter and six months ended October 31, 2025, while facing a Nasdaq minimum bid price non-compliance notice and ongoing FDA clinical hold challenges.

PharmaCyte Biotech reported a significant net loss in Q1 2026, driven by fair value adjustments, as it continues to address an FDA clinical hold and re-evaluate its core programs.

PharmaCyte Biotech's Q3 2025 report highlights efforts to address the FDA clinical hold, investment in TNF Pharmaceuticals, and a decrease in operating expenses.

PharmaCyte Biotech's Q2 2025 report reveals a significant net income driven by investment gains, alongside ongoing efforts to address an FDA clinical hold on their pancreatic cancer therapy.

PharmaCyte Biotech reports a significant net income for the first quarter of 2025, primarily driven by gains from investments, despite ongoing operational challenges and a clinical hold on their lead program.

PharmaCyte Biotech's Form 10-K filing reveals ongoing challenges with an FDA clinical hold on its pancreatic cancer therapy, impacting development timelines and requiring significant resources to address regulatory concerns.

PharmaCyte Biotech reports a significant net income increase driven by investment gains, while facing ongoing FDA clinical hold challenges and strategic reevaluation of its core cancer therapy programs.

PharmaCyte Biotech's annual report reveals a year of strategic reevaluation, reduced spending, and ongoing efforts to address an FDA clinical hold on its pancreatic cancer therapy.

Wayne Remell Walker, a Director of PharmaCyte Biotech, Inc., reported multiple transactions in common stock on March 31, 2026.

Michael M Abecassis, a Director of PharmaCyte Biotech, Inc., reported multiple transactions in common stock on March 31, 2026.

Jonathan Schechter, a Director of PharmaCyte Biotech, Inc., reported multiple transactions in common stock on March 31, 2026.

Robert Weinstein, a Director of PharmaCyte Biotech, Inc., reported multiple transactions in common stock on March 31, 2026.

PharmaCyte Biotech Director Robert Weinstein acquired 119,170 stock options with an exercise price of $0.67, vesting on the next annual meeting date.

PharmaCyte Biotech, Inc. director Wayne Remell Walker reports the acquisition of stock options.

PharmaCyte Biotech, Inc. calls a special meeting to approve a significant share issuance for recent financing and an increase in its equity incentive plan.

PharmaCyte Biotech, Inc. has filed a definitive proxy statement with the SEC.

PharmaCyte Biotech will hold its annual stockholder meeting virtually on April 24, 2025, to elect directors, ratify the appointment of its accounting firm, and conduct an advisory vote on executive compensation.

PharmaCyte Biotech will hold its annual stockholder meeting virtually on April 29, 2024, to elect directors and ratify the appointment of its accounting firm.

PharmaCyte Biotech reports 74.00% beneficial ownership of Q/C Technologies via preferred stock and warrants following shareholder approval.

Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher report a continued passive beneficial ownership of 4.99% in PharmaCyte Biotech, Inc. as of December 31, 2025, constrained by blocker provisions.

Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher have disclosed a combined beneficial ownership of 9.99% of PharmaCyte Biotech, Inc.'s common stock, as detailed in an amended Schedule 13G filing.

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have jointly reported a 9.9% beneficial ownership stake in PharmaCyte Biotech, Inc., primarily through warrants.

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed beneficial ownership of approximately 9.99% of PharmaCyte Biotech, Inc.'s common stock as of December 31, 2024, through a Schedule 13G filing.